Cybin Inc. (CYBN)
USD 9.46
(-0.11%)
USD 9.46
(-0.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.09 Million CAD | 27.67% |
| 2022 | 7.9 Million CAD | 31.93% |
| 2021 | 5.99 Million CAD | 2179.09% |
| 2020 | 263 Thousand CAD | 0.0% |
| 2019 | 263 Thousand CAD | 1826.32% |
| 2018 | 13.65 Thousand CAD | -14.3% |
| 2017 | 15.93 Thousand CAD | -89.4% |
| 2016 | 150.29 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.81 Million CAD | -52.31% |
| 2023 Q3 | 8.5 Million CAD | -8.01% |
| 2023 FY | 10.09 Million CAD | 27.67% |
| 2023 Q1 | 6.4 Million CAD | 13.1% |
| 2023 Q4 | 10.09 Million CAD | 18.73% |
| 2023 Q2 | 9.24 Million CAD | 44.31% |
| 2022 Q2 | 4.88 Million CAD | -23.78% |
| 2022 FY | 7.9 Million CAD | 31.93% |
| 2022 Q4 | 5.66 Million CAD | 29.62% |
| 2022 Q3 | 4.36 Million CAD | -10.51% |
| 2022 Q1 | 6.4 Million CAD | -19.01% |
| 2021 Q1 | 6.56 Million CAD | 9.58% |
| 2021 FY | 5.99 Million CAD | 2179.09% |
| 2021 Q4 | 7.9 Million CAD | 30.39% |
| 2021 Q3 | 6.06 Million CAD | -0.1% |
| 2021 Q2 | 6.07 Million CAD | -7.57% |
| 2020 FY | 263 Thousand CAD | 0.0% |
| 2020 Q3 | 8.37 Million CAD | 15722.95% |
| 2020 Q2 | 52.95 Thousand CAD | -97.65% |
| 2020 Q1 | 2.25 Million CAD | 0.0% |
| 2020 Q4 | 5.99 Million CAD | -28.47% |
| 2019 FY | 263 Thousand CAD | 1826.32% |
| 2018 FY | 13.65 Thousand CAD | -14.3% |
| 2017 FY | 15.93 Thousand CAD | -89.4% |
| 2016 FY | 150.29 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 9.14 Million USD | -10.375% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -324.916% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 92.892% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 77.597% |
| Azitra, Inc. | 2.2 Million USD | -358.421% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -169.514% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -54.351% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 44.692% |
| CEL-SCI Corporation | 17.31 Million USD | 41.687% |
| iBio, Inc. | 7.41 Million USD | -36.248% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 74.11% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -42.411% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 78.209% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 19.328% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -76.503% |
| NanoViricides, Inc. | 1.35 Million USD | -643.022% |
| Oragenics, Inc. | 1.79 Million USD | -461.456% |
| BiomX Inc. | 55.07 Million USD | 81.669% |
| BiomX Inc. | 55.07 Million USD | 81.669% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 80.151% |
| Palatin Technologies, Inc. | 10.85 Million USD | 6.982% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 55.609% |